Automating clinical-grade allogeneic cell therapy manufacturing: NorthX and Mendus case study in tech transfer, efficiency, and scale-out

Thursday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Automating clinical-grade allogeneic cell therapy manufacturing: NorthX and Mendus case study in tech transfer, efficiency, and scale-out

This webinar examines the automation decisions that shape technology transfer, scaling, and GMP-compliant production in cell therapy manufacturing. Drawing on a real-world case study from NorthX Biologics and Mendus, and using an allogeneic dendritic cell immune therapy as the worked example, the speakers will show how early process design influences transfer success, product consistency, and the route to clinical and commercial supply.

Attendees will also gain a practical overview of automation with hollow-fiber perfusion technology and its applications, including CAR-T, TCR-T, MSCs, and iPSCs, and of when and how to bring automation into a workflow.

Attend this webinar to:

Apply a framework for deciding when and how to implement automation in support of clinical and commercial manufacturing goals
Learn from a real-world technology transfer case study covering the move from biotech development to clinical-grade, automated cell manufacturing
Understand how hollow-fiber bioreactor technology and continuous perfusion support process development, GMP-compliant production, and future scaling
Gain insights into what needs to be in place to reduce hands-on labor, lower process variability, and support robust manufacturing under real-world challenges, such as scaling and deviations

Ola Tuvesson

Chief Technology Officer at NorthX Biologics

Ola Tuvesson has been active in the field of biotechnology and CMC for the last 20 years and is currently serving as the Chief Technology Officer at NorthX Biologics. Ola has a proven track record of supporting successful biologics programs ranging from development to commercial GMP manufacturing within all fields including biologics, vaccines and C&GT.

Throughout his career, Ola has a strong commitment to innovation and strategic partnerships, driving the advancement of technologies and solutions in the biologics sector, supporting the realization of scientific advancements into tangible and compliant products that can make an actual difference.

Maria Knaub, PhD

Global Scientific Engagement Manager at Terumo Blood and Cell Technologies

Maria Knaub, PhD is the Global Scientific Engagement Manager at Terumo Blood and Cell Technologies, where she collaborates with leading cell and gene therapy developers, academic institutions, and manufacturing organizations worldwide to advance automation and scalable manufacturing solutions. Having previously worked as a Field Application Scientist, she brings extensive experience in technology transfer, process optimization, implementation, and automation of cell manufacturing workflows.

With a PhD in Molecular Biology and a career spanning research, project management, and field support in ATMP manufacturing, Maria provides a practical perspective on how organizations can bridge the gap between early clinical manufacturing and future commercial scale. Her work focuses on identifying manufacturing bottlenecks, enabling successful process transfer, and translating scientific innovation into robust, reproducible manufacturing processes. Through global scientific collaborations and engagement with key opinion leaders across the CGT ecosystem, she has developed a broad understanding of the operational challenges and strategies that drive successful adoption of manufacturing automation.

In 42 Days

You have registered for this webinar